Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flu-Hemato-Rando study: high-dose versus standard-dose inactivated influenza vaccine in adults treated for hematological cancer
2023-505357-40-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Liège
- Start
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of influenza vaccine (quadrivalent, high-dose) and Fluarix Quadrivalent in influenza (2 arms), sponsored by Centre Hospitalier Universitaire de Liège. Planned start Sep 2023; status: authorised.
02
Drugs
influenza vaccine (quadrivalent, high-dose)Fluarix Quadrivalent
03
Conditions
influenza
Beyond the preview
Go deeper on 2023-505357-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505357-40-00.